Inclusion Criteria:

- Histological or cytological diagnosis of inoperable stage IIIB/IV non-squamous NSCLC

- At least one measurable lesion (RECIST criteria)

- Life expectancy > 3 months

- ECOG performance status 0-2

- Adequate hematologic function: WBC ≥ 3.0×109 /L，ANC ≥ 1.5×109 /L，Hb ≥ 90 g/L，PLT ≥
100×109 /L

- Adequate renal, hepatic and coagulation function

- Written informed consent

Exclusion Criteria:

- With uncontrollable malignant pleural effusion or ascites

- Thoracic or abdominal surgery within 28 days prior to study entry

- History of cerebral stroke or TIA within 6 months prior to study entry

- With uncontrollable hypertension, hypertensive emergency or hypertensive
encephalopathy

- Arrhythmia in need of antiarrhythmic treatment, history of angina pectoris,
myocardial infarction, myocardial ischemia or congestive heart failure (> NYHA class
II)

- With serious infection (> NCI CTC grade 2)

- Gastrointestinal perforation, fistula formation, and/or intra‑abdominal abscess
within 6 months prior to study entry

- Symptomatic brain metastases

- Patient who has epilepsy

- History of HIV infection or chronic hepatitis B or C

- Allergic to any of the study drugs

- Pregnant or lactating women